LBA
LYRA

Letko, Brosseau & Associates’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Letko, Brosseau & Associates’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-638
Closed -$8.83K – 106
2024
Q2 		$8.83K Hold
638
– – ﹤0.01% 104
2024
Q1 		$198K Hold
638
– – ﹤0.01% 95
2023
Q4 		$167K Hold
638
– – ﹤0.01% 89
2023
Q3 		$125K Hold
638
– – ﹤0.01% 91
2023
Q2 		$131K Buy
+638
New +$88.6K ﹤0.01% 91

Other funds holding LYRA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SEI Investments
SEI Investments Oaks, Pennsylvania $108B AUM 26.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Letko, Brosseau & Associates's LYRA Position: Q3 2024 in Review

Letko, Brosseau & Associates sold out of LYRA THERAPEUTICS INC (LYRA) in Q3 2024, closing a stake of 638 shares — an estimated $8.83K sold.

Letko, Brosseau & Associates first reported a position in LYRA in Q2 2023 and held it in 5 quarters. The position peaked at $198K in Q1 2024. 62 funds tracked by Wall St. Rank hold LYRA as of Q3 2024.

  • Letko, Brosseau & Associates reported no remaining LYRA THERAPEUTICS INC position as of Q3 2024 after selling out during the quarter.
  • Letko, Brosseau & Associates sold 638 LYRA THERAPEUTICS INC shares in Q3 2024, an estimated $8.83K.
  • Letko, Brosseau & Associates first reported a position in LYRA THERAPEUTICS INC in Q2 2023 and held it in 5 quarters.
  • Letko, Brosseau & Associates's LYRA THERAPEUTICS INC position peaked at $198K in Q1 2024.
  • 62 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q3 2024.

Based on Letko, Brosseau & Associates's 13F filing for Q3 2024, filed 7 Nov 2024.